When Two Immunotherapy Rights Make a Wrong – Genetic Engineering & Biotechnology News
Genetic Engineering & Biotechnology News |
When Two Immunotherapy Rights Make a Wrong
Genetic Engineering & Biotechnology News Recent advances in immunotherapy have given many cancer patients stricken with tumors intractable to current therapies hope for meaningful remission times. While researchers continue to try and understand the intricacies of the immune system’s response … |
UCalgary News |
Researchers discover new immunotherapy combination effective at …
UCalgary News “We’ve been looking at these cancer drugs the wrong way — as tumour-targeting drugs — instead of what we now feel is their most important biological role: as … |
Medical Xpress |
Gene therapy using ‘junk DNA’ could lower risk for heart disease
Medical Xpress Scientists from UCLA and the Howard Hughes Medical Institute successfully used a gene that suppresses cholesterol levels as part of a treatment to reduce … Familial Hypercholesterolemia: “Junk” RNA May Facilitate Gene …MedicalResearch.com (blog) |
|
FDA Raids One Stem Cell Lab and Warns Another in Regulatory Push
Bloomberg On Monday, the Food and Drug Administration released a warning letter it sent last week to Florida-based U.S. Stem Cell Inc. for selling unapproved stem–cell treatments and injecting them into patients’ spinal cords. And it raided a San Diego-based … |
FierceBiotech |
CSL Behring buys Calimmune for early stem cell, gene therapy boost
FierceBiotech CSL Behring has paid out $91 million upfront for biotech Calimmune and gains a preclinical asset for sickle cell disease and β-thalassemia, adding to its blood disease pipeline. The biotech is working on ex vivo hematopoietic stem cell (HSC) gene … CSL snags a preclinical stem cell therapy in $416M Calimmune buyout, plans to spin out HIV effortEndpoints News CSL Behring to Acquire Biotech Company Calimmune and its Proprietary Stem Cell Gene Therapy PlatformMarkets Insider CSL spends $114m to buy US cell and gene therapy companyThe Australian |
FierceBiotech |
CSL Behring buys Calimmune for early stem cell, gene therapy boost
FierceBiotech CSL Behring has paid out $91 million upfront for biotech Calimmune and gains a preclinical asset for sickle cell disease and β-thalassemia, adding to its blood disease pipeline. The biotech is working on ex vivo hematopoietic stem cell (HSC) gene … CSL snags a preclinical stem cell therapy in $416M Calimmune buyout, plans to spin out HIV effortEndpoints News CSL Behring to Acquire Biotech Company Calimmune and its Proprietary Stem Cell Gene Therapy PlatformMarkets Insider CSL spends $114m to buy US cell and gene therapy companyThe Australian |